APX3330

APX3330 has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Nov 2, 2026: “Blood cell mutations linked to inflammatory bowel disease in women”.

Intervention

1 paper studies it1 findingUpdated

PubChem

See all 1 papers on APX3330

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country; 1 trial, none about aging.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • 1 trial, none about aging
  • Funders: National Cancer Institute and 3 more
  • 1 of 1 trial sponsored by its developers
  • Humans1

What did studies of APX3330 find?

1

Studies of APX3330 measured 1 outcome; the most studied are inflammatory bowel disease (1 study).

Inflammatory bowel disease

downin mice1

1 study
  1. APX3330 decreases inflammatory bowel disease in Dnmt3a-mutant CHIP-IBD mice.

    “Treatment with the APE1/redox factor 1 inhibitor APX3330 ameliorated CHIP-IBD driven by the Dnmt3a mutation.”

    Animalsin Dnmt3a-mutant CHIP-IBD micecolon

    Blood cell mutations linked to inflammatory bowel disease in women

    Blood

More on Inflammatory bowel disease

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months
Blood

Blood cell mutations linked to inflammatory bowel disease in women

In the UK Biobank, women carrying these mutations had a 1.33-fold higher relative risk of inflammatory bowel disease than women without them.In the UK Biobank, women carrying these mutations had a 1.33-fold higher relative risk of inflammatory bowel disease than women without them.

Cohort · 426,609 peopleInflammation